Together, these results demonstrate the capacity of Fgfr2 deletion in zG cells to fully prevent the development of βCat–driven adrenal hyperplasia and to block aldosterone excess following activation of RAAS. The gene discussed is FGFR2; the disease is congenital adrenal hyperplasia.